SOPHiA GENETICS takes home two accolades at the Healthcare Asia Medtech Awards
The company was recognised for its genomic application, Solid Tumor Plus Solution (STS+).
SOPHiA GENETICS bagged both the Hospital Partnership of the Year - Australia and Oncology Product Innovation of the Year - Australia trophies at the recently concluded Healthcare Asia Medtech Awards. The awards programme aims to recognise medtech companies that have made a remarkable impact on their clients and cancer management.
SOPHiA GENETICS was recognised for assisting one of its Indian clients with their Solid Tumor Solution plus, a solid tumor profiling application that accelerates the assessment and reporting of 42 DNA-based variants and 137 RNA-based gene fusion detection by combining analytical performance* with the SOPHiA DDM™ platform interpretation capabilities.
SOPHiA GENETICS Solid Tumor Plus Solution is an all-in-one targeted profiling solution that supports the detection of SNVs, large indels, gene amplification, MSI status and gene fusions. The solution is part of the SOPHiA DDM™ platform that combines highly optimized analytical performance* for the aforementioned variants, variant-preclassification and streamlined interpretation in one fully integrated bioinformatic (from data to report) workflow. The workflow offers several features that simplify and accelerate the assessment and reporting of complex genomic variants in the context of solid tumor profiling.
On top of accuracy, ease of use and flexibility, the workflow guarantees data protection and support for its users, to ensure confidence and fast resolution of any disruption. Ultimately – users can easily export their analysis in a report that can be shared with their peers.